From Kibong’oto Infectious Diseases Hospital to Tanzania Infectious Diseases Institute: A milestone for infectious disease preparedness in Tanzania and the continent

A century after its establishment as a tuberculosis (TB) sanatorium, Kibong’oto Infectious Diseases Hospital (KIDH) has reached a defining milestone in its history. After more than a decade of sustained investment in scientific expertise, research infrastructure, and institutional systems, KIDH has been elevated into the Tanzania Infectious Diseases Institute (TIDI), a significant step forward for Tanzania’s infectious disease preparedness.

On 24 July 2026, through a Government Gazette Notice No. 216 of 2026, the Government of Tanzania formally established TIDI. The new institute expands KIDH’s mandate beyond specialized clinical care to include a broader national role in infectious disease research, preparedness, rapid response, and scientific capacity development.

This significant milestone coincides with 100 years of TB services at Kibong’oto. From its origins as a TB sanatorium in 1926, the institution has evolved into a national institute positioned to address a wider range of infectious disease threats.

“The transition to TIDI represents the most significant transformation in Kibong’oto’s 100-year history. It broadens our role from specialised infectious-disease care to a national platform for research, surveillance, preparedness, training and innovation, while strengthening Tanzania’s contribution to regional and global health security.”

— Professor Stellah Mpagama, Director of Research Training and Innovations Tanzania Infectious Diseases Institute (TIDI)

Prof Stellah Mpagama at Tanzania Infectious Diseases Institute (TIDI)

This transformation reflects the changing health landscape in Tanzania and the wider East African region, where emerging and re-emerging infectious diseases continue to pose a growing risk. The establishment of TIDI represents an important step towards strengthening Tanzania’s ability to anticipate, investigate, and respond to future health threats. Strengthening national instituitions that can connect specialized clinical care with research, evidence generation, clinical trials and rapid response is increasingly important.

The transformation did not happen overnight

For more than a decade, KIDH has received sustained investment towards strengthening its technical, research, and administrative capacity. During this period, the institution developed specialized expertise in managing drug-resistant TB and other infectious diseases, expanded its outreach to underserved and marginalized communities, and strengthened its laboratory and research infrastructure.

The Kibong’oto Public Health Laboratory

KIDH also established the capacity to conduct Phase II and III clinical trials in TB and HIV, demonstrating its growing role as a centre for high-quality clinical research. These investments provided a strong foundation for the institution’s expanded mandate.

Intensive Care Unit Building

More recently, participation in the Advancing Capacity for Early Phase Trials for Pandemics and Epidemics in Africa (ACCEPT-Africa) consortium has supported the next stage of this journey. Through the consortium, KIDH/TIDI is strengthening its readiness to conduct early-phase clinical trials, including the development of Phase I capabilities, stronger clinical and research systems, and multidisciplinary research teams.

Collaboration with the Infectious Diseases Institute (IDI) at Makerere University, and other consortium partners has also created opportunities for technical learning, knowledge exchange, and regional collaboration. These partnerships are helping strengthen the capacity of African institutions to prepare for and respond to future epidemics and pandemics.

Additionally, investment in people has been central to KIDH’s transformation. The institution has supported the development of a growing generation of researchers and research leaders, including more than 25 MSc trainees, 19 PhD trainees, and 15 postdoctoral trainees. It has also developed seven research administration personnel and strengthened grant management and institutional governance.

“I was a PhD fellow in the ReMODEL training programme at TIDI, formerly KIDH, which was supported by EDCTP2. Through this programme, I networked and worked with several other consortia, including the Training Health Researchers in Vocational Excellence (ThRIVE-2) and the Application of Genomics and Modelling to the Control of Virus Pathogens in East Africa (GeMVi), the latter supported by NIHR. The programme strengthened my early-career research skills, including conceptual, technical and interpersonal skills in pathogen genomics, which have created a spillover effect into the ACCEPT-Africa consortium.”

— Dr. Shabani Mziray, Laboratory Scientist

Together, these investments have strengthened the expertise and systems needed to manage complex research programmes, attract competitive funding, and generate evidence that responds to Tanzania’s health priorities.

The impact of TIDI extends beyond the institution itself

For Tanzanian researchers and young scientists, the revised institutional mandate creates new opportunities to build careers in advanced infectious disease research while contributing to solutions for health challenges facing their own communities.

For patients and communities, the institute offers the potential for greater access to specialized expertise and research-informed care. It also provides a stronger platform for evidence generated in Tanzania to inform responses to the health threats affecting Tanzanian communities.

The transformation into the Tanzania Infectious Diseases Institute (TIDI) is more than a change of name. From its beginnings as a TB sanatorium in 1926 to a national infectious diseases institute a century later, TIDI’s journey demonstrates what sustained investment in people, infrastructure, institutions and partnerships can achieve over time. For the ACCEPT-Africa consortium, this milestone provides a tangible example of how investments in clinical trial readiness and scientific capacity can contribute to lasting institutional development, while creating opportunities to strengthen Tanzania’s research ecosystem and its contribution to regional pandemic preparedness.

As TIDI begins this new chapter, it is better positioned to advance clinical and infectious disease research, generate evidence, develop scientific leaders and strengthen Tanzania’s capacity to respond to emerging health threats. The next phase will focus on translating this expanded mandate into stronger research infrastructure, early-phase clinical research capability and new opportunities for collaboration. Together, TIDI and ACCEPT-Africa can help build a stronger platform for pandemic research in Tanzania and across Africa, bringing researchers, institutions, policymakers and partners together to share expertise, deepen collaboration and contribute to a more resilient continental research ecosystem.

Tanzania Infectious Diseases Institute’s (TIDI) Radiology building

Written by Onai Yambazi, Communications Officer, ACCEPT-Africa consortium

Three Consortia, One Mandate: Inside Uganda’s EPSILONs Unified Pandemic Preparedness and Response System

The lull between outbreaks is often defined by a quiet, dangerous erosion: trained personnel move on, specialized laboratories pivot, and institutional memory fades. When the next virus occurs, Africa’s scientific community is forced to rebuild its response efforts from scratch.

On July 31, 2026, inside the Sande McKinnell Centre at Makerere University’s Infectious Diseases Institute (IDI) three Ugandan-based Epidemic and Pandemic Sciences Innovation and Leadership Networks (EPSILONs) consortia committed to a different approach: build connections before the next outbreak, not during it.

The Uganda EPSILON Mini-Launch brought together: Advancing Capacity for Early Phase Trials for Pandemics and Epidemics in Africa (ACCEPT-Africa), Prevention and Response to Emerging viruses with Pandemic potential in Africa Epsilon (PREPARE) and Strengthening Health systems capacity in Africa for Pandemic Equity and Responsiveness (SHARPER) – three consortia working across different but interconnected areas of pandemic preparedness under the Africa Pandemic Sciences Collaborative. Their meeting marked a shift from parallel efforts towards greater collaboration and long-term capacity building.

Beyond Parallel Silos

Each consortium brings a distinct capability to Uganda’s pandemic preparedness.

ACCEPT-Africa focuses on clinical trials and medical countermeasures, building the capacity to design and conduct early-phase clinical trials in Africa. PREPARE is focused on an early vaccine and diagnostic development for priority pathogens

 helping generate timely evidence on emerging pathogens. SHARPER focuses on the social, ethical and community dimensions that underpin effective research and response.

“ACCEPT-Africa was built to move fast when speed matters most,” said Dr Christine Sekaggya-Wiltshire, who leads the consortia. “But no single network can prepare a country alone. Standing alongside SHARPER and PREPARE today means we can pool our strengths, share what each of us has learned, and respond as one system instead of three.”

 “Preparedness cannot live in silos,” added Dr Andrew Kambugu, IDI’s Executive Director. “Today’s Mini-Launch is IDI’s commitment to a Uganda where our pandemic science networks plan together, train together, and respond together, long before the next outbreak begins.”

The gathering brought together representatives from Uganda’s Ministry of Health, Makerere University College of Health Sciences, Africa CDC, the Science for Africa Foundation and research institutions, reflecting the range of actors needed to translate scientific capacity into effective preparedness.

The Case for Each Other

The morning’s presentations showed why the three consortia need each other.

Dr Daniel Kiiza laid out ACCEPT-Africa’s ambition to build a sustainable pool of independent African research scientists capable of designing and running early-phase trials rather than Africa remaining a site where products developed elsewhere are simply tested.

Dr Joyce Namulondo described PREPARE’s push to close the gap between an outbreak starting and a pathogen being understood. Using influenza as an example, she highlighted the role of genomic surveillance in tracking rapidly evolving viruses and generating evidence that can inform vaccine development.

Nimrod Muhumuza presented SHARPER’s case that no amount of laboratory excellence survives contact with a community that does not trust the response. The consortium’s guiding line was that researchers must not simply take science to communities but build science with them.

Together, the presentations made a simple point: detecting a pathogen, developing a medical response, and ensuring that communities can participate in and benefit from that response are not separate challenges. They are parts of the same pandemic preparedness and response system.

Building Science with the Community

The afternoon’s panel discussions moved quickly past administrative goals to address the stark realities of field deployment. When asked how response teams can navigate mistrust such as the tragic attacks on Ebola treatment units seen in neighbouring DRC during the 2026 outbreak, the consensus was unequivocal: technical excellence fails if community trust is absent.

Dr Moses Mulumba spoke about SHARPER’s focus on an “Afrocentric” approach to research, including examining whether research standards developed elsewhere adequately reflect African contexts and values. The approach also asks a broader question: whether communities are merely sources of data or participants who should experience meaningful benefits from the research.

Dr Christine Sekaggya-Wiltshire put it plainly: “We go beyond just the clinical trials; we build synergies with communities to understand their perceptions towards the work we are doing.”

Empowering Tomorrow’s Science Leaders

Central to the Africa Pandemic Sciences Collaborative’s mandate is ensuring that early-career researchers do not remain in administrative shadows. To operationalize this, Dr Sekaggya described ACCEPT-Africa’s Catalyst Groups in pharmacokinetics, clinical trials, bio-ethics and behavioral science, where junior scientists apply for grants under senior mentorship rather than waiting years to lead their first study.

Dr. Linda Murungi, Program Manager for the Africa Pandemic Sciences Collaborative, widened the definition of capacity building further. “It is not only about scientists,” she reminded the room, “but also the finance officers, grants managers and policy specialists who make African-led research possible. This institutional infrastructure may be less visible, but without it, no scientific breakthrough can survive.”

As the mini-launch concluded in Kampala, the significance of bringing the three consortia together was becoming clearer. Uganda’s pandemic preparedness does not depend on any single laboratory, research network or discipline. It depends on whether those capabilities can connect when they are needed.

up-arrow white-up-arrow